Two competing statins similarly effective

The battle of the statins has resulted in a draw, as the data from the two-year SATURN study of over 1,300 patients are in. Scientists found that AstraZeneca s Crestor (rosuvastatin) and Pfizer s Lipitor (atorvastatin) actually have comparable effects when it comes to lowering the volume of fatty deposits in the arteries of patients with coronary disease a conclusion that surprised both cardiologists and AstraZeneca.

Simply stated, says ACSH s Dr. Ruth Kava, this is good news. Now people have the choice of taking either drug without sacrificing any of the benefits.